TZDs: Targeting Insulin Resistance Amid Controversy

If you read the headlines about Avandia and Actos, you may be wondering whether you should stop or continue taking this medication. Here's the latest word.



In May 2007, the New England Journal of Medicine published an analysis of research that found people taking Avandia had an increased risk of having a heart attack.

In June 2007, the FDA ordered that a "black box" warning be added to the label for rosiglitazone (Avandia) and a different drug in the same class, pioglitazone (Actos). This warning strengthens existing warnings about the risk for heart attack.

In July 2007, the FDA issued a nonbinding recommendation that while there is evidence of increased risk of heart attack, it doesn't warrant removing Avandia from the market.

Where does this leave the million or so people with type 2 diabetes who've been taking these drugs to increase their insulin sensitivity and improve blood glucose control? And if you're one of them, how should you weigh the potential benefit of these drugs against the increased risk?